Provided by Tiger Trade Technology Pte. Ltd.

AbbVie

261.59
-1.7000-0.65%
Post-market: 262.981.39+0.53%19:57 EDT
Volume:4.39M
Turnover:1.15B
Market Cap:462.33B
PE:73.90
High:265.36
Open:264.60
Low:261.59
Close:263.29
52wk High:269.39
52wk Low:190.75
Shares:1.77B
Float Shares:1.76B
Volume Ratio:1.23
T/O Rate:0.25%
Dividend:6.83
Dividend Rate:2.61%
EPS(TTM):3.54
EPS(LYR):2.36
ROE:6225.00%
ROA:10.51%
PB:-77.90
PE(LYR):110.84

Loading ...

AbbVie Doubles Down: SiRNA Player Adarx Targets $372M Nasdaq IPO At $1.74B Valuation

Bellwether Stocks Movement
·
Sep 22

AbbVie Announces European Commission Approval of Rinvoq (Upadacitinib)

Reuters
·
Sep 22

AbbVie Says EU Approves Rinvoq for Children with Polyarticular Juvenile Idiopathic Arthritis

Reuters
·
Sep 22

Abbvie Announces European Commission Approval of Rinvoq® (Upadacitinib) for the Treatment of Children with Active Polyarticular Juvenile Idiopathic Arthritis

THOMSON REUTERS
·
Sep 22

Abbvie - Rinvoq Approved in EU for Pjia in Patients Aged Two Years and Older

THOMSON REUTERS
·
Sep 22

Biogen Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 22

Nvidia, QIA-Backed Iambic Therapeutics Files for US IPO as Biotech Boom Rolls On

Reuters
·
Sep 22

Pharma Sector Doubles Down on AI to Slash Costs, Timelines

Reuters
·
Sep 21

AbbVie, Iambic Sign Multiyear Drug Discovery Deal

MT Newswires Live
·
Sep 21

AbbVie Partners with Iambic to Accelerate AI-Driven Small-Molecule Drug Discovery

Reuters
·
Sep 21

Abbvie and Iambic Announce Collaboration to Accelerate AI-Driven Drug Discovery

THOMSON REUTERS
·
Sep 21

Abbvie - Iambic to Receive Upfront Payment, Milestone Payments, and Tiered Royalties from Collaboration

THOMSON REUTERS
·
Sep 21

Abbvie - Partnership to Accelerate Small Molecule Drug Discovery in Immunology, Neuroscience, Oncology

THOMSON REUTERS
·
Sep 21

Adarx Pharmaceuticals: IPO Price Expected Between $15 and $17 Per Share

Reuters
·
Sep 21

ADARx Pharmaceuticals to Sell 21.9 Million Shares at $15-$17 Each in IPO

Dow Jones
·
Sep 21

Drug Developer ADARx Seeks $1.74 Billion Valuation in US IPO

Reuters
·
Sep 21

AbbVie presents new Vraylar data at Psych Congress 2026

TIPRANKS
·
Sep 18

AbbVie Says Real-World Studies Show Vraylar Improves Symptoms in MDD, Bipolar I Depression

Reuters
·
Sep 18

AbbVie Targets Dry Eye Market Upside With New ABBV-444 Trial Update

TIPRANKS
·
Sep 18

US Regulators Urge More Research on Testosterone Therapy for Women as Experts Debate Benefits, Risks

Reuters
·
Sep 18